Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

Figure 4

sCEACAM1 and LDH are elevated in melanoma patients who fail to respond to immunotherapy. sCEACAM1 (a) and LDH (b) levels were measured in clinically derived serum samples of AJCC stage IV metastatic melanoma patients that underwent immunotherapy with tumor infiltrating lymphocytes before as well as at 2 points after treatment (except for PD patients who passed away before the later time point). Statistics were assayed by regular Student’s -test.

(a)

(b)